Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer

ESMO Open

Volumn 2, Issue , 2017, Pages

  Nishio, Makoto ^a   Hida, Toyoaki ^b   Atagi, Shinji ^c   Sakai, Hiroshi ^d   Nakagawa, Kazuhiko ^e   Takahashi, Toshiaki ^f   Nogami, Naoyuki ^g   Saka, Hideo ^h   Takenoyama, Mitsuhiro ⁱ   Maemondo, Makoto ^j   Ohe, Yuichiro ^k   Nokihara, Hiroshi ^k   Hirashima, Tomonori ^l   Tanaka, Hiroshi ^m   Fujita, Shiro ⁿ   Takeda, Koji ^o   Goto, Koichi ^p   Satouchi, Miyako ^q   Isobe, Hiroshi ^r   Minato, Koichi ^s   Sumiyoshi, Naoki ^t   Tamura, Tomohide ^u   more..

^a CANCER INSTITUTE HOSPITAL   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

^d SAITAMA CANCER CENTER   (Japan)

^e KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f SHIZUOKA CANCER CENTER   (Japan)

^g NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^h NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

ⁱ NATIONAL KYUSHU CANCER CENTER   (Japan)

^j Miyagi Cancer Center   (Japan)

^k NATIONAL CANCER CENTER HOSPITAL   (Japan)

^l OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

^m NIIGATA CANCER CENTER HOSPITAL   (Japan)

ⁿ INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

^o OSAKA CITY GENERAL HOSPITAL   (Japan)

^p NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^q HYOGO CANCER CENTER   (Japan)

^r KKR Sapporo Medical Center   (Japan)

^s GUNMA PREFECTURAL CANCER CENTER   (Japan)

^t ONO PHARMACEUTICAL CO   (Japan)

^u ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

more..

Author keywords

nivolumab; non small cell lung cancer; non squamous histology; PD L1; programmed cell death 1

Indexed keywords

EID: 85021805419     PISSN: None     EISSN: 20597029     Source Type: Journal    
DOI: 10.1136/esmoopen-2016-000108     Document Type: Article

References (19)

1. Cancer Information Service NCC, Japan. Cancer registry and statistics [in Japanese]. Secondary Cancer registry and statistics [in Japanese]. 2015. http://www. mhlw. go. jp/toukei/saikin/hw/jinkou/ kakutei14/dl/11-h7. pdf (accessed 28 Jul 2016).
2. Cancer Information Service NCC, Japan. Cancer registry and statistics [in Japanese]. Secondary Cancer registry and statistics [in Japanese]. 2016. http://ganjoho. jp/data/reg-stat/statistics/dl/cancer- incidence(1975-2012). xls (accessed 28 Jul 2016).
3. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. J Thorac Oncol 2011;6:244-85.
4. Krzakowski M, Ramlau R, Jassem J, et al. Phase III trial comparing vinflunine with docetaxel in second-line advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy. J Clin Oncol 2010;28:2167-73.
5. Pallis AG, Agelaki S, Agelidou A, et al. A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/ metastatic non-small cell lung cancer. BMC Cancer 2010;10:633.
6. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-97.
7. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64.
8. Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008;26:677-704.
9. Zhang Y, Huang S, Gong D, et al. Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer. Cell Mol Immunol 2010;7:389-95.
10. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015;373:1627-39.
11. Mirsadraee S, Oswal D, Alizadeh Y, et al. The 7th lung cancer TNM classification and staging system: review of the changes and implications. World J Radiol 2012;4:128-34.
12. Gettinger SN, Horn L, Gandhi L, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2015;33:2004-12.
13. Wolchok JD, Weber JS, Maio M, et al. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. Ann Oncol 2013;24:2174-80.
14. Prieto PA, Yang JC, Sherry RM, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 2012;18:2039-47.
15. Rizvi NA, Mazières J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): A phase 2, single-arm trial. Lancet Oncol 2015;16:257-65.
16. Hellmann MD, Creelan BC, Woo K, et al. Smoking history and response to nivolumab in patients with advanced NSCLCs. Ann Oncol 2014;25:iv426-70.
17. Govindan R, Ding L, Griffith M, et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 2012;150:1121-34.
18. Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348:124-8.
19. Passiglia F, Bronte G, Bazan V, et al. PD-L1 expression as predictive biomarker in patients with NSCLC: A pooled analysis. Oncotarget 2016;7:19738-47.